BMS' Opdivo denied first-line melanoma indication; Biogen's long-acting hemophilia med nabs EU approval;

> Fresh off an FDA victory just days ago, Bristol-Myers Squibb's ($BMY) Opdivo hit an obstacle in melanoma; the agency denied a first-line use in that disease, saying it needs more data in patients with BRAF mutations. Report

> Biogen ($BIIB) and Sobi's new hemophilia A med Elocta won approval in Europe, the first longer-acting treatment in that disease type for the region. Release

> China is zeroing in on drugs made by domestic pharma companies, threatening growth among multinationals that have benefited not only from newer products but from their own "branded generics." Report

> Spain's Almirall agreed to buy dermatology specialist Poli Group, part of its bid to move into specialty meds after selling off its respiratory drugs to AstraZeneca ($AZN) last year. Release

> Sanofi Pasteur says the first doses of its new injectable polio vaccine, ShanIPV, will soon be rolling out in India, a market where oral polio vaccines are customary. Release

And Finally... Blue Latitude Health picked up a PMEA award for its work on Eli Lilly's ($LLY) Medical Information Cascade, an online medical portal. Release